MX2007012103A - Formulaciones deposito inyectables y metodos para proporcionar una liberacion sostenida de composiciones de nanoparticulas. - Google Patents
Formulaciones deposito inyectables y metodos para proporcionar una liberacion sostenida de composiciones de nanoparticulas.Info
- Publication number
- MX2007012103A MX2007012103A MX2007012103A MX2007012103A MX2007012103A MX 2007012103 A MX2007012103 A MX 2007012103A MX 2007012103 A MX2007012103 A MX 2007012103A MX 2007012103 A MX2007012103 A MX 2007012103A MX 2007012103 A MX2007012103 A MX 2007012103A
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- weight
- surface stabilizer
- compound
- ziprasidone
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000002105 nanoparticle Substances 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 abstract 1
- 229960000607 ziprasidone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nanotechnology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67112405P | 2005-04-13 | 2005-04-13 | |
| PCT/IB2006/001094 WO2006109183A1 (en) | 2005-04-13 | 2006-04-10 | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007012103A true MX2007012103A (es) | 2007-11-20 |
Family
ID=36602931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007012103A MX2007012103A (es) | 2005-04-13 | 2006-04-10 | Formulaciones deposito inyectables y metodos para proporcionar una liberacion sostenida de composiciones de nanoparticulas. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080193542A1 (enExample) |
| EP (1) | EP1874268A1 (enExample) |
| JP (1) | JP2008538751A (enExample) |
| KR (1) | KR20070119678A (enExample) |
| CN (1) | CN101166514A (enExample) |
| AU (2) | AU2006233345A1 (enExample) |
| BR (1) | BRPI0609299A2 (enExample) |
| CA (1) | CA2605153A1 (enExample) |
| IL (1) | IL186131A0 (enExample) |
| MX (1) | MX2007012103A (enExample) |
| NZ (1) | NZ561950A (enExample) |
| RU (1) | RU2407529C2 (enExample) |
| WO (1) | WO2006109183A1 (enExample) |
| ZA (1) | ZA200708188B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| WO2001032148A1 (en) | 1999-10-29 | 2001-05-10 | Euro-Celtique, S.A. | Controlled release hydrocodone formulations |
| CN101317825A (zh) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
| BRPI0414082A (pt) * | 2003-09-02 | 2006-10-24 | Pfizer Prod Inc | formas de dosagem de liberação sustentada de ziprasidona |
| US20080305161A1 (en) * | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| EP1901722A4 (en) * | 2005-06-20 | 2011-06-15 | Elan Pharma Int Ltd | NANOTEHOUS COMPOSITIONS WITH CONTROLLED RELEASE FROM ARYL-HETEROCYCLIC COMPOUNDS |
| MX2007016151A (es) * | 2005-06-20 | 2008-03-06 | Elan Pharma Int Ltd | Composiciones de liberacion controlada y en forma de nano-particulas que comprenden compuestos aril-heterociclicos. |
| AU2008274185B2 (en) * | 2007-07-12 | 2014-07-03 | Janssen Sciences Ireland Uc | Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile |
| EP2629775A4 (en) | 2010-10-18 | 2014-06-11 | Dainippon Sumitomo Pharma Co | INJECTABLE FORMULATION WITH DELAYED RELEASE |
| CA2832410C (en) | 2011-04-15 | 2019-07-23 | Janssen Pharmaceutica Nv | Freeze dried drug nanosuspensions |
| CN104814926A (zh) * | 2015-04-08 | 2015-08-05 | 中国药科大学 | 一种鲁拉西酮纳米混悬剂及其制备方法 |
| US20170079985A1 (en) * | 2015-09-21 | 2017-03-23 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| JP2020511483A (ja) | 2017-03-20 | 2020-04-16 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 徐放性オランザピン製剤 |
| CN109998991A (zh) * | 2019-04-28 | 2019-07-12 | 中国药科大学 | 一种盐酸鲁拉西酮长效肌肉注射纳米混悬液及其制备方法 |
| KR102847306B1 (ko) * | 2021-08-13 | 2025-08-18 | 단국대학교 천안캠퍼스 산학협력단 | 결정형 몬테루카스트를 포함하는 지속성 현탁 주사제 및 이의 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
| US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| MXPA05002561A (es) * | 2002-10-25 | 2005-05-05 | Pfizer Prod Inc | Nuevas formulaciones de liberacion prolongada inyectables. |
| AU2003300814A1 (en) * | 2002-12-04 | 2004-06-23 | Dr. Reddy's Laboratories Inc. | Polymorphic forms of ziprasidone and its hydrochloride |
| US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| BRPI0414082A (pt) * | 2003-09-02 | 2006-10-24 | Pfizer Prod Inc | formas de dosagem de liberação sustentada de ziprasidona |
-
2006
- 2006-04-10 KR KR1020077023308A patent/KR20070119678A/ko not_active Abandoned
- 2006-04-10 NZ NZ561950A patent/NZ561950A/en not_active IP Right Cessation
- 2006-04-10 WO PCT/IB2006/001094 patent/WO2006109183A1/en not_active Ceased
- 2006-04-10 BR BRPI0609299-3A patent/BRPI0609299A2/pt not_active IP Right Cessation
- 2006-04-10 CN CNA2006800144209A patent/CN101166514A/zh active Pending
- 2006-04-10 EP EP06744618A patent/EP1874268A1/en not_active Withdrawn
- 2006-04-10 JP JP2008505990A patent/JP2008538751A/ja not_active Withdrawn
- 2006-04-10 RU RU2007137846/15A patent/RU2407529C2/ru not_active IP Right Cessation
- 2006-04-10 AU AU2006233345A patent/AU2006233345A1/en not_active Abandoned
- 2006-04-10 MX MX2007012103A patent/MX2007012103A/es not_active Application Discontinuation
- 2006-04-10 CA CA002605153A patent/CA2605153A1/en not_active Abandoned
- 2006-04-10 US US11/911,457 patent/US20080193542A1/en not_active Abandoned
-
2007
- 2007-09-20 IL IL186131A patent/IL186131A0/en unknown
- 2007-09-25 ZA ZA200708188A patent/ZA200708188B/xx unknown
-
2010
- 2010-05-05 AU AU2010201801A patent/AU2010201801A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006233345A1 (en) | 2006-10-19 |
| CA2605153A1 (en) | 2006-10-19 |
| RU2407529C2 (ru) | 2010-12-27 |
| US20080193542A1 (en) | 2008-08-14 |
| AU2010201801A1 (en) | 2010-05-27 |
| KR20070119678A (ko) | 2007-12-20 |
| BRPI0609299A2 (pt) | 2010-03-23 |
| WO2006109183A1 (en) | 2006-10-19 |
| EP1874268A1 (en) | 2008-01-09 |
| NZ561950A (en) | 2010-09-30 |
| CN101166514A (zh) | 2008-04-23 |
| JP2008538751A (ja) | 2008-11-06 |
| IL186131A0 (en) | 2008-01-20 |
| RU2007137846A (ru) | 2009-06-20 |
| ZA200708188B (en) | 2008-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080305161A1 (en) | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions | |
| AU2010201801A1 (en) | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions | |
| JP6694682B2 (ja) | ナノ粒子活性物質組成物におけるフレーク状凝集の軽減 | |
| US20080166411A1 (en) | Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles | |
| HU226070B1 (en) | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters | |
| HU226608B1 (hu) | Vízoldhatalan anyagok mikrorészecskéit tartalmazó készítmények és ezek elõállítására szolgáló eljárások | |
| HUT77526A (hu) | Gyógyszerészeti nanoszuszpenzió gyógyszerhatóanyag adagolásra megnövelt telítési oldhatóságú és oldódási sebességű rendszerként | |
| EP1874267A1 (en) | Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles | |
| CN112494492B (zh) | 阿立哌唑前体药物组合物 | |
| RS62932B1 (sr) | Postupak pripreme sterilne nanokristalne suspenzije oftamološkog vodenog flutikazon propionata forme a | |
| HK1117740A (en) | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions | |
| HK40049829A (en) | Aripiprazole prodrug compositions | |
| HK40049829B (zh) | 阿立哌唑前体药物组合物 | |
| HK1235663A1 (en) | Reduction of flake-like aggregation in nanoparticulate meloxicam compositions | |
| HK1235663A (en) | Reduction of flake-like aggregation in nanoparticulate meloxicam compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |